{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:13Z","timestamp":1790704333769,"version":"4.1.0"},"reference-count":102,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010135","name":"Finska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["2016"],"award-info":[{"award-number":["2016"]}],"id":[{"id":"10.13039\/100010135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010135","name":"Finska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["2018-2023"],"award-info":[{"award-number":["2018-2023"]}],"id":[{"id":"10.13039\/100010135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["2019-2023"],"award-info":[{"award-number":["2019-2023"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010600","name":"Tays","doi-asserted-by":"publisher","award":["VTR 2016-2023 Tukis\u00e4\u00e4ti\u00f6 2019-2022"],"award-info":[{"award-number":["VTR 2016-2023 Tukis\u00e4\u00e4ti\u00f6 2019-2022"]}],"id":[{"id":"10.13039\/501100010600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["TYH 2016-2020"],"award-info":[{"award-number":["TYH 2016-2020"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["Oncology clinic 2019-2022"],"award-info":[{"award-number":["Oncology clinic 2019-2022"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019783","name":"Relander Foundation","doi-asserted-by":"publisher","award":["2020-2022"],"award-info":[{"award-number":["2020-2022"]}],"id":[{"id":"10.13039\/501100019783","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of the European Medicines Agency approval of S-1 in metastatic colorectal cancer (mCRC), this analysis provides more detailed safety and efficacy information, and data regarding metastasectomy and\/or local ablative therapy (LAT), on the mCRC patients from the original study.\nMaterials and methods: This retrospective cohort study was conducted at 12 European centers. The primary endpoint was recurrence of cardiotoxicity after switch. For this analysis, safety data are reported for 78 mCRC patients from the CardioSwitch cohort (N = 200). Detailed efficacy and outcomes data were available for 66 mCRC patients.\nResults: Data for the safety of S-1 in mCRC patients were similar to the original CardioSwitch cohort and that expected for FP-based treatment, with no new concerns. Recurrent cardiotoxicity (all grade 1) with S-1-based treatment occurred in 4\/78 (5%) mCRC patients; all were able to complete FP treatment. Median progression-free survival from initiation of S-1-based treatment was 9.0 months and median overall survival 26.7 months. Metastasectomy and\/or LAT was performed in 33\/66 (50%) patients, and S-1 was successfully used in recommended neoadjuvant\/conversion or adjuvant-like combination regimens and schedules as for standard FPs.\nInterpretation: S-1 is a safe and effective FP alternative when mCRC patients are forced to discontinue 5-FU or capecitabine due to cardiotoxicity and can be safely used in the standard recommended regimens, settings, and schedules.<\/jats:p>","DOI":"10.2340\/1651-226x.2024.24023","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T02:18:17Z","timestamp":1714702697000},"page":"248-258","source":"Crossref","is-referenced-by-count":4,"title":["Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)"],"prefix":"10.2340","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8060-0193","authenticated-orcid":false,"given":"Sampsa","family":"Kinos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4427-1123","authenticated-orcid":false,"given":"Helga","family":"Hagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9760-0840","authenticated-orcid":false,"given":"P\u00e4ivi","family":"Halonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5210-2891","authenticated-orcid":false,"given":"Leena-Maija","family":"Soveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7987-4154","authenticated-orcid":false,"given":"Mary","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-0586","authenticated-orcid":false,"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1985-2046","authenticated-orcid":false,"given":"Jan-Erik","family":"Fr\u00f6din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-6214","authenticated-orcid":false,"given":"Halfdan","family":"Sorbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-1170","authenticated-orcid":false,"given":"Eetu","family":"Heerv\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-3949","authenticated-orcid":false,"given":"Gabor","family":"Liposits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5912-496X","authenticated-orcid":false,"given":"Raija","family":"Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-1881","authenticated-orcid":false,"given":"Annika","family":"\u00c5lgars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-3045","authenticated-orcid":false,"given":"Raija","family":"Ristam\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4116-2260","authenticated-orcid":false,"given":"Tapio","family":"Salminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1469-5654","authenticated-orcid":false,"given":"Maarit","family":"B\u00e4rlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1412-5985","authenticated-orcid":false,"given":"Carl-Henrik","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-4315","authenticated-orcid":false,"given":"Ray","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-3733","authenticated-orcid":false,"given":"Rebecka","family":"R\u00f6ckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-1239","authenticated-orcid":false,"given":"Petra","family":"Flygare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-7124","authenticated-orcid":false,"given":"Johannes","family":"Kwakman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5305-1619","authenticated-orcid":false,"given":"Arco","family":"Teske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-1445","authenticated-orcid":false,"given":"Cornelis","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-791X","authenticated-orcid":false,"given":"Bengt","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7124-3515","authenticated-orcid":false,"given":"Pia","family":"\u00d6sterlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"58550","doi-asserted-by":"crossref","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO Clinical Prac-tice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1);10\u201332.","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"58551","doi-asserted-by":"crossref","unstructured":"Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974\u201384.","DOI":"10.1016\/j.ctrv.2013.03.005"},{"key":"58552","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.005","DOI":"10.1016\/j.ctrv.2013.03.005"},{"key":"58553","doi-asserted-by":"crossref","unstructured":"Sorrentino MF, Kim J, Foderaro AE, Truesdell AG. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J. 2012;19:453\u20138.","DOI":"10.5603\/CJ.2012.0084"},{"key":"58554","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5603\/CJ.2012.0084","DOI":"10.5603\/CJ.2012.0084"},{"key":"58555","doi-asserted-by":"crossref","unstructured":"Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysio-logy of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47.","DOI":"10.1186\/2050-6511-15-47"},{"key":"58556","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/2050-6511-15-47","DOI":"10.1186\/2050-6511-15-47"},{"key":"58557","doi-asserted-by":"crossref","unstructured":"Dyhl-Polk A, Vaage-Nilsen M, Schou M, Vistisen KK, Lund CM, K\u00fcmler T. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Acta Oncol. 2020;59:475\u201383.","DOI":"10.1080\/0284186X.2019.1711164"},{"key":"58558","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2019.1711164","DOI":"10.1080\/0284186X.2019.1711164"},{"key":"58559","doi-asserted-by":"crossref","unstructured":"Kwakman JJ, Simkens LH, Mol L, Kok WE, Koopman M, Punt CJ. Incidence of capecita-bine-related cardiotoxicity in different treatment schedules of metasta-tic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch colorectal cancer group. Eur J Cancer. 2017;76:93\u201399.","DOI":"10.1016\/j.ejca.2017.02.009"},{"key":"58560","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.009","DOI":"10.1016\/j.ejca.2017.02.009"},{"key":"58561","doi-asserted-by":"crossref","unstructured":"Jurczyk M, Kr\u00f3l M, Midro A, Kurnik-\u0141ucka M, Poniatowski A, Gil K. Cardiotoxicity of fluo-ropyrimidines: Epidemiology, mechanisms, diagnosis, and manage-ment. J Clin Med. 2021;10:4426.","DOI":"10.3390\/jcm10194426"},{"key":"58562","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm10194426","DOI":"10.3390\/jcm10194426"},{"key":"58563","doi-asserted-by":"crossref","unstructured":"Lu Y, Deng S, Dou Q, et al. Treatment-related coronary disorders of fluoropyrimidine ad-ministration: a systematic review and meta-analysis. Front Pharmacol. 2022;13:885699.","DOI":"10.3389\/fphar.2022.885699"},{"key":"58564","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphar.2022.885699","DOI":"10.3389\/fphar.2022.885699"},{"key":"58565","doi-asserted-by":"crossref","unstructured":"Deboever G, Hiltrop N, Cool M, Lambrecht G. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardio-toxicity. Clin Colorectal Cancer. 2013;12:8\u201314.","DOI":"10.1016\/j.clcc.2012.09.003"},{"key":"58566","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clcc.2012.09.003","DOI":"10.1016\/j.clcc.2012.09.003"},{"key":"58567","doi-asserted-by":"crossref","unstructured":"Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin On-col. 2010;28:1547\u201353.","DOI":"10.1200\/JCO.2009.25.4706"},{"key":"58568","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2009.25.4706","DOI":"10.1200\/JCO.2009.25.4706"},{"key":"58569","doi-asserted-by":"crossref","unstructured":"er Veer E, Ngai LL, Valkenhoef GV, et al. Capecitabine, 5-fluorouracil and S-1-based regi-mens for previously untreated advanced oesophagogastric cancer: a network meta-analysis. Sci Rep. 2017;7:7142.","DOI":"10.1038\/s41598-017-07750-3"},{"key":"58570","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41598-017-07750-3","DOI":"10.1038\/s41598-017-07750-3"},{"key":"58571","doi-asserted-by":"crossref","unstructured":"Kwakman JJM, Baars A, van Zweeden AA, de Mol P, Koopman M, Kok WEM, Punt CJA. Case series of patients treated with the oral fluoropyrimidine S-1 after cape-citabine-induced coronary artery vasospasm. Eur J Cancer. 2017;81:130\u20134.","DOI":"10.1016\/j.ejca.2017.05.022"},{"key":"58572","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2017.05.022","DOI":"10.1016\/j.ejca.2017.05.022"},{"key":"58573","doi-asserted-by":"crossref","unstructured":"Osterlund P, Kinos S, Pfeiffer P, et al. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open. 2022;7:100427.","DOI":"10.1016\/j.esmoop.2022.100427"},{"key":"58574","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100427","DOI":"10.1016\/j.esmoop.2022.100427"},{"key":"58575","doi-asserted-by":"crossref","unstructured":"Punt CJA, Kwakman JJM, Mol L, PLCRC working group. Long-term safety data on S-1 ad-ministered after previous intolerance to capecitabine-containing sys-temic treatment for metastatic colorectal cancer. Clin Colorectal Can-cer. 2022;21:229\u201335.","DOI":"10.1016\/j.clcc.2022.02.004"},{"key":"58576","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clcc.2022.02.004","DOI":"10.1016\/j.clcc.2022.02.004"},{"key":"58577","doi-asserted-by":"crossref","unstructured":"Derksen JWG, Smit KC, May AM, Punt CJA. Systematic review and non-inferiority meta-analysis of randomised phase II\/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of pati-ents with metastatic colorectal cancer. Eur J Cancer. 2022;166:73\u201386.","DOI":"10.1016\/j.ejca.2022.02.004"},{"key":"58578","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2022.02.004","DOI":"10.1016\/j.ejca.2022.02.004"},{"key":"58579","doi-asserted-by":"crossref","unstructured":"Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch colorectal cancer group. Ann Oncol. 2017;28:1288\u201393.","DOI":"10.1093\/annonc\/mdx122"},{"key":"58580","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdx122","DOI":"10.1093\/annonc\/mdx122"},{"key":"58581","unstructured":"European Medicines Agency. EMA\/CHMP\/714788\/2021. Summary of positive opinion [In-ternet]. [cited 12-08-2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-teysuno-ii-45_en.pdf"},{"key":"58582","unstructured":"eysuno (S-1) summary of product characteristics [Internet]. [cited 12-08-2023]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/teysuno"},{"key":"58583","doi-asserted-by":"crossref","unstructured":"Glimelius B. Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Ad-juvant Therapy Group. Ann Oncol. 1993;4:235\u201340.","DOI":"10.1093\/oxfordjournals.annonc.a058463"},{"key":"58584","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058463","DOI":"10.1093\/oxfordjournals.annonc.a058463"},{"key":"58585","doi-asserted-by":"crossref","unstructured":"S\u00f8rbye H, Dahl O. Nordic 5-fluorouracil\/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic co-lorectal cancer. Acta Oncol. 2003;42:827\u201331.","DOI":"10.1080\/02841860310018972"},{"key":"58586","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/02841860310018972","DOI":"10.1080\/02841860310018972"},{"key":"58587","doi-asserted-by":"crossref","unstructured":"Guren TK, Thomsen M, Kure EH, et al. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NOR-DIC-VII study. Br J Cancer. 2017;116:1271\u20138.","DOI":"10.1038\/bjc.2017.93"},{"key":"58588","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/bjc.2017.93","DOI":"10.1038\/bjc.2017.93"},{"key":"58589","doi-asserted-by":"crossref","unstructured":"Glimelius B, S\u00f8rbye H, Balteskard L, et al. A randomized phase III multicenter trial compa-ring irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus\/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol. 2008;19:909\u201314.","DOI":"10.1093\/annonc\/mdm588"},{"key":"58590","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdm588","DOI":"10.1093\/annonc\/mdm588"},{"key":"58591","doi-asserted-by":"crossref","unstructured":"Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377:2103\u201314.","DOI":"10.1016\/S0140-6736(11)60613-2"},{"key":"58592","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(11)60613-2","DOI":"10.1016\/S0140-6736(11)60613-2"},{"key":"58593","doi-asserted-by":"crossref","unstructured":"Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil com-pared with fluorouracil alone as first-line treatment for metastatic co-lorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041\u20137.","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"58594","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(00)02034-1","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"58595","doi-asserted-by":"crossref","unstructured":"Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated me-tastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077\u201385.","DOI":"10.1016\/S1470-2045(13)70154-2"},{"key":"58596","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(13)70154-2","DOI":"10.1016\/S1470-2045(13)70154-2"},{"key":"58597","doi-asserted-by":"crossref","unstructured":"Winther SB, Liposits G, Skuladottir H, et al. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2019;4:376\u201388.","DOI":"10.1016\/S2468-1253(19)30041-X"},{"key":"58598","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S2468-1253(19)30041-X","DOI":"10.1016\/S2468-1253(19)30041-X"},{"key":"58599","doi-asserted-by":"crossref","unstructured":"de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938\u201347.","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"58600","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2000.18.16.2938","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"58601","doi-asserted-by":"crossref","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006\u201312.","DOI":"10.1200\/JCO.2007.14.9898"},{"key":"58602","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2007.14.9898","DOI":"10.1200\/JCO.2007.14.9898"},{"key":"58603","doi-asserted-by":"crossref","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013\u201319.","DOI":"10.1200\/JCO.2007.14.9930"},{"key":"58604","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2007.14.9930","DOI":"10.1200\/JCO.2007.14.9930"},{"key":"58605","doi-asserted-by":"crossref","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","DOI":"10.1056\/NEJMoa032691"},{"key":"58606","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa032691","DOI":"10.1056\/NEJMoa032691"},{"key":"58607","doi-asserted-by":"crossref","unstructured":"Nishizawa Y, Haraguchi N, Kim H, et al. Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). BMC Cancer. 2021;21:947.","DOI":"10.1186\/s12885-021-08690-y"},{"key":"58608","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-021-08690-y","DOI":"10.1186\/s12885-021-08690-y"},{"key":"58609","doi-asserted-by":"crossref","unstructured":"Baba H, Yamada Y, Takahari D, et al. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. ESMO Open. 2017;2:e000135.","DOI":"10.1136\/esmoopen-2016-000135"},{"key":"58610","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/esmoopen-2016-000135","DOI":"10.1136\/esmoopen-2016-000135"},{"key":"58611","doi-asserted-by":"crossref","unstructured":"Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for me-tastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853\u201360.","DOI":"10.1016\/S1470-2045(10)70181-9"},{"key":"58612","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(10)70181-9","DOI":"10.1016\/S1470-2045(10)70181-9"},{"key":"58613","doi-asserted-by":"crossref","unstructured":"Sadahiro S, Suzuki T, Okada K, et al. Oral S-1 with 24-h infusion of irinotecan plus Bevaci-zumab versus FOLFIRI plus Bevacizumab as first-line chemotherapy for metastatic colorectal cancer: an open-label randomized Phase II trial. Oncology. 2020;98:637\u201342.","DOI":"10.1159\/000507293"},{"key":"58614","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000507293","DOI":"10.1159\/000507293"},{"key":"58615","doi-asserted-by":"crossref","unstructured":"Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in pa-tients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol. 2018;29:624\u201331.","DOI":"10.1093\/annonc\/mdx816"},{"key":"58616","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdx816","DOI":"10.1093\/annonc\/mdx816"},{"key":"58617","doi-asserted-by":"crossref","unstructured":"Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13:993\u20131001.","DOI":"10.1016\/S1470-2045(12)70345-5"},{"key":"58618","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(12)70345-5","DOI":"10.1016\/S1470-2045(12)70345-5"},{"key":"58619","doi-asserted-by":"crossref","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory me-tastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","DOI":"10.1056\/NEJMoa1414325"},{"key":"58620","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1414325","DOI":"10.1056\/NEJMoa1414325"},{"key":"58621","doi-asserted-by":"crossref","unstructured":"Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously trea-ted metastatic colorectal cancer (CORRECT): an international, multi-centre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312.","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"58622","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"58623","doi-asserted-by":"crossref","unstructured":"Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619\u201329.","DOI":"10.1016\/S1470-2045(15)70156-7"},{"key":"58624","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(15)70156-7","DOI":"10.1016\/S1470-2045(15)70156-7"},{"key":"58625","doi-asserted-by":"crossref","unstructured":"Arnold D, Prager GW, Quintela A, et al. Beyond second-line therapy in patients with me-tastatic colorectal cancer: a systematic review. Ann Oncol. 2018;29:835\u201356.","DOI":"10.1093\/annonc\/mdy038"},{"key":"58626","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdy038","DOI":"10.1093\/annonc\/mdy038"},{"key":"58627","doi-asserted-by":"crossref","unstructured":"Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29\u201337.","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"58628","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(12)70477-1","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"58629","doi-asserted-by":"crossref","unstructured":"Argil\u00e9s G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291\u2013305.","DOI":"10.1016\/j.annonc.2020.06.022"},{"key":"58630","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2020.06.022","DOI":"10.1016\/j.annonc.2020.06.022"},{"key":"58631","doi-asserted-by":"crossref","unstructured":"Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8:191\u2013202.","DOI":"10.1517\/14740330902733961"},{"key":"58632","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1517\/14740330902733961","DOI":"10.1517\/14740330902733961"},{"key":"58633","doi-asserted-by":"crossref","unstructured":"ensen SA, S\u00f8rensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58:487\u201393.","DOI":"10.1007\/s00280-005-0178-1"},{"key":"58634","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00280-005-0178-1","DOI":"10.1007\/s00280-005-0178-1"},{"key":"58635","doi-asserted-by":"crossref","unstructured":"Punt CJA, Heinemann V, Maughan T, et al. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluo-ropyrimidine S-1 in metastatic colorectal cancer. ESMO Open. 2023;8:101199.","DOI":"10.1016\/j.esmoop.2023.101199"},{"key":"58636","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101199","DOI":"10.1016\/j.esmoop.2023.101199"},{"key":"58637","unstructured":"Saif MW, Garcon MC, Rodriguez G, Rodriguez T. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series. In Vivo. 2013;27:531\u20134."},{"key":"58638","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Sara J, Lobo R, et al. Bolus 5-fluorouracil (5-FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coro-nary vasospasm with infusional 5-FU or capecitabine. Clin Colorectal Cancer. 2019;18:52\u20137.","DOI":"10.1016\/j.clcc.2018.09.006"},{"key":"58639","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clcc.2018.09.006","DOI":"10.1016\/j.clcc.2018.09.006"},{"key":"58640","doi-asserted-by":"crossref","unstructured":"Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann Oncol. 2014;25:117\u201321.","DOI":"10.1093\/annonc\/mdt479"},{"key":"58641","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdt479","DOI":"10.1093\/annonc\/mdt479"},{"key":"58642","doi-asserted-by":"crossref","unstructured":"Batra A, Rigo R, Hannouf MB, Cheung WY. Real-world safety and efficacy of raltitrexed in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2021;20:e75\u201381.","DOI":"10.1016\/j.clcc.2020.09.006"},{"key":"58643","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clcc.2020.09.006","DOI":"10.1016\/j.clcc.2020.09.006"},{"key":"58644","doi-asserted-by":"crossref","unstructured":"Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2008;12:iii\u2013162.","DOI":"10.3310\/hta12150"},{"key":"58645","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3310\/hta12150","DOI":"10.3310\/hta12150"},{"key":"58646","doi-asserted-by":"crossref","unstructured":"Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer. 2008;44:2204\u201311.","DOI":"10.1016\/j.ejca.2008.07.002"},{"key":"58647","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2008.07.002","DOI":"10.1016\/j.ejca.2008.07.002"},{"key":"58648","doi-asserted-by":"crossref","unstructured":"Folprecht G, Grothey A, Alberts S, Raab HR, K\u00f6hne CH. Neoadjuvant treatment of unre-sectable colorectal liver metastases: correlation between tumour re-sponse and resection rates. Ann Oncol. 2005;16:1311\u20139.","DOI":"10.1093\/annonc\/mdi246"},{"key":"58649","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdi246","DOI":"10.1093\/annonc\/mdi246"},{"key":"58650","doi-asserted-by":"crossref","unstructured":"Osterlund P, Salminen T, Soveri LM, et al. Repeated centralized multidisciplinary team as-sessment of resectability, clinical behavior, and outcomes in 1086 Fin-nish metastatic colorectal cancer patients (RAXO): a nationwide prospective intervention study. Lancet Reg Health Eur. 2021;3:100049.","DOI":"10.1016\/j.lanepe.2021.100049"},{"key":"58651","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100049","DOI":"10.1016\/j.lanepe.2021.100049"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/24023\/46001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/24023\/46001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:05:14Z","timestamp":1756404314000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/24023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":102,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2024.24023","relation":{},"ISSN":["1651-226X","0284-186X"],"issn-type":[{"value":"1651-226X","type":"electronic"},{"value":"0284-186X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}